Literature DB >> 18819928

A Key role for cyclic AMP-responsive element binding protein in hypoxia-mediated activation of the angiogenesis factor CCN1 (CYR61) in Tumor cells.

Ronit Meyuhas1, Eli Pikarsky, Einat Tavor, Avihu Klar, Rinat Abramovitch, Jacob Hochman, Tal Goshen Lago, Alik Honigman.   

Abstract

Hypoxia is a prominent feature of solid tumors known to contribute to malignant progression and therapeutic resistance. Cancer cells adapt to hypoxia using various pathways, allowing tumors to thrive in a low oxygen state. Induction of new blood vessel formation via the secretion of proangiogenic factors is one of the main adaptive responses engaged by tumor cells under hypoxic conditions. Hypoxia-inducible factor 1 (HIF-1) is a transcription factor that plays a pivotal role in mediating such responses. In addition, several other transcription factors have also been implicated in hypoxic gene regulation, either independently or in cooperation with HIF-1. In this work, we show that the expression of the angiogenesis-related, immediate early gene CCN1 (formerly known as CYR61), considered to be involved in tumor growth and invasiveness, is enhanced upon hypoxia stress primarily in a protein kinase A and cyclic AMP-responsive element binding protein (CREB) and CRE-dependent manner in various cell lines. The hypoxia-mediated activation of the CCN1 promoter is independent of HIF-1 and HIF-2, as shown by small interfering RNA knockdown. We identify the cis element in the mouse CCN1 promoter responsible for CREB binding to be one of two partial CRE sites present in the promoter. Moreover, we report for the first time that CREB-mediated CCN1 transcription is enhanced in hypoxic regions of tumors in vivo. Identifying and characterizing the molecular mechanisms that govern the response of tumors to hypoxia may be instrumental to identify the tumors that will respond favorably to inhibition of angiogenesis and thus lead to the development of treatments that could complement hypoxia-inducing treatment modalities.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18819928     DOI: 10.1158/1541-7786.MCR-07-2086

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  15 in total

1.  Cyr61 mediates hepatocyte growth factor-dependent tumor cell growth, migration, and Akt activation.

Authors:  C Rory Goodwin; Bachchu Lal; Xin Zhou; Sandra Ho; Shuli Xia; Alexandra Taeger; Jamie Murray; John Laterra
Journal:  Cancer Res       Date:  2010-03-16       Impact factor: 12.701

2.  Cyr61 silencing reduces vascularization and dissemination of osteosarcoma tumors.

Authors:  N Habel; M Vilalta; O Bawa; P Opolon; J Blanco; O Fromigué
Journal:  Oncogene       Date:  2014-07-28       Impact factor: 9.867

Review 3.  CCN1/CYR61: the very model of a modern matricellular protein.

Authors:  Lester F Lau
Journal:  Cell Mol Life Sci       Date:  2011-07-31       Impact factor: 9.261

4.  Mechanism of CREB recognition and coactivation by the CREB-regulated transcriptional coactivator CRTC2.

Authors:  Qianyi Luo; Kristin Viste; Janny Concha Urday-Zaa; Ganesan Senthil Kumar; Wen-Wei Tsai; Afsaneh Talai; Kelly E Mayo; Marc Montminy; Ishwar Radhakrishnan
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-04       Impact factor: 11.205

5.  Activated cAMP response element binding protein is overexpressed in human mesotheliomas and inhibits apoptosis.

Authors:  Arti Shukla; Marcus W Bosenberg; Maximilian B MacPherson; Kelly J Butnor; Nicholas H Heintz; Harvey I Pass; Michele Carbone; Joseph R Testa; Brooke T Mossman
Journal:  Am J Pathol       Date:  2009-10-08       Impact factor: 4.307

6.  Vulnerability of the developing heart to oxygen deprivation as a cause of congenital heart defects.

Authors:  Doreswamy Kenchegowda; Hongbin Liu; Keyata Thompson; Liping Luo; Stuart S Martin; Steven A Fisher
Journal:  J Am Heart Assoc       Date:  2014-05-22       Impact factor: 5.501

Review 7.  Control of CREB expression in tumors: from molecular mechanisms and signal transduction pathways to therapeutic target.

Authors:  André Steven; Barbara Seliger
Journal:  Oncotarget       Date:  2016-06-07

8.  The α and Δ isoforms of CREB1 are required to maintain normal pulmonary vascular resistance.

Authors:  Lili Li; Katherine Howell; Michelle Sands; Mark Banahan; Stephen Frohlich; Simon C Rowan; Roisín Neary; Donal Ryan; Paul McLoughlin
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

9.  CCN1/Cyr61-PI3K/AKT signaling promotes retinal neovascularization in oxygen-induced retinopathy.

Authors:  Yu Di; Yiou Zhang; Qingzhu Nie; Xiaolong Chen
Journal:  Int J Mol Med       Date:  2015-10-12       Impact factor: 4.101

10.  Functional consequence of the p53 codon 72 polymorphism in colorectal cancer.

Authors:  Venkat R Katkoori; Upender Manne; Lakshmi S Chaturvedi; Marc D Basson; Pam Haan; Daniel Coffey; Harvey L Bumpers
Journal:  Oncotarget       Date:  2017-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.